Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PALB2 R170fs |
| Therapy | Talazoparib |
| Indication/Tumor Type | bladder urachal adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PALB2 R170fs | bladder urachal adenocarcinoma | predicted - sensitive | Talazoparib | Case Reports/Case Series | Actionable | In a Phase II trial, Talzenna (talazoparib) treatment resulted in a clinical benefit rate (CBR) of 22.8% (18/79, 1 complete and 7 partial responses, 10 with stable disease >/=24 weeks) in patients with advanced solid tumors harboring mutations in DNA damage repair genes, including a partial response lasting 17 weeks in a urachal adenocarcinoma patient harboring PALB2 R170fs14 (PMID: 39085400; NCT02286687). | 39085400 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39085400) | Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. | Full reference... |